TITLE

Shades of gray

AUTHOR(S)
Lee, Jaimy
PUB. DATE
October 2011
SOURCE
Modern Healthcare;10/10/2011, Vol. 41 Issue 41, p10
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article discusses concerns on the provision of back-ordered drugs by secondary distributors to hospitals and pharmacies that often cost over 10 times the product's average wholesale price. According to the author, the lack of uniformity in the secondary market with the lack of information and certification system, and allegations of price-gouging, have emerged as concerns of hospital pharmacists and others in the industry.
ACCESSION #
66918402

 

Related Articles

  • Shades of gray. Lee, Jaimy // Modern Healthcare;10/10/2011, Vol. 41 Issue 41, p10 

    The article discusses concerns on the provision of back-ordered drugs by secondary distributors to hospitals and pharmacies that often cost over 10 times the product's average wholesale price. According to the author, the lack of uniformity in the secondary market with the lack of information...

  • Pressure mounts on drug supplies in Greece as some firms demand cash. Photopoulos, Julianna // BMJ: British Medical Journal;7/18/2015, Vol. 351 Issue 8017, ph3804 

    The article reports on the impact of financial crisis in Greece on drug supplies as of July 18, 2015, making reference to Panhellenic Pharmaceutical Association's claim that some drug wholesalers were asking pharmacists to pay in cash and restricting orders on some drugs.

  • Pharmaceutical Companies' Variation Of Drug Prices Within And Among Countries Can Improve Long-Term Social Well-Being. Lichtenberg, Frank R. // Health Affairs;Aug2011, Vol. 30 Issue 8, p1539 

    Drug prices vary considerably across and within countries. On average, pharmaceutical companies charge lower prices in low-income countries than in industrialized nations. Manufacturers' ability to price products differently for different markets-a practice known as price...

  • Illegitimate companies threaten patients' receipt of FDA-approved drugs. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;10/1/2013, Vol. 70 Issue 19, p1646 

    The article focuses on the health risks posed by the purchase of unapproved medications in the U.S. During the 2012-13 period, several letters were sent by the Food and Drug Administration (FDA) to clinics and medical practices regarding these medications. According to Allergan Inc. attorney...

  • Proposal for New Drug User Fee Program Addresses Drug Safety.  // Chemical Market Reporter;3/11/2002, Vol. 261 Issue 10, p4 

    Focuses on the proposal for drug user fee program which addresses drug safety by the pharmaceutical industry and the U.S. Food & Drug Administration. Significance of the proposal; Estimated amount allotted for drug reviews in the fiscal year 2002.

  • Buying medicine online is risky business. Benton, David; Williamson, Lindsey; Stodart, Kathy // Kai Tiaki Nursing New Zealand;May2014, Vol. 20 Issue 4, p27 

    No abstract available.

  • Generics mull user fees again?  // Medical Marketing & Media;Apr98, Vol. 33 Issue 4, p36 

    Reports on the requests of the National Association of Pharmaceutical Manufacturers (NAPM) for its members to support generic drug user fees. Reference to a bid for widespread support from the generic drug industry; Information on the NAPM's annual conference.

  • Revitalizing Pharmaceutical Innovation For Global Health. Hoffman, Steven J.; Pogge, Thomas // Health Affairs;Feb2011, Vol. 30 Issue 2, p367 

    A letter to the editor is presented regarding the article on access to medicine in the January 2011 issue.

  • How Have User Fees Affected the FDA? Olson, Mary K. // Regulation;Spring2002, Vol. 25 Issue 1, p20 

    Deals with a legislation passed by the U.S. Congress which introduced prescription drug user fees for Food and Drug Administration new-drug review. Effects of the user fee program on pharmaceutical firms; Drug review targets; Implications of the reform for the relative importance of drug...

  • Cost of Drug Approval Rises. Agres, Ted // Drug Discovery & Development;Feb2007, Vol. 10 Issue 2, p20 

    The article discusses the cost of drug approval in the U.S. The pharmaceutical and biotechnology industries are facing similar financial and product pipeline challenges in 2007 as they did in 2006. User fees under Prescription Drug User Fee Act (PDUFA) have escalated by hugely in fiscal 2007....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics